Breast Cancer Australia Breast Cancer Australia


The publication of the results of clinical trials research in a scientific journal or a periodic publication:
  • fulfils the researchers’ ethical obligations to research participants and the general community;
  • contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.
Since we first began more than 35 years ago, the ANZBCTG has contributed to more than 900 publications through our breast cancer clinical trials research program. The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name.

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as "open access"; however some require a subscription.

Search for Publications

1. Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Wapnir IL, Gelber S, Anderson SJ, Mamounas EP, Robidoux A, Marin M, Nortier JWR, Geyer Jr CE, Paterson AHG, Lang I, Price KN, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S, on behalf of CALOR trial investigators.
Annals of Surgical Oncology 2017; 24 : 398-406 (epub 23 Sept 2016)
2. Eyelash and eyebrow madarosis: A qualitative study to assess the perceptions and experience of Australian patients with breast cancer.
Morris K, Winstanley J, Boyle F, O'Reily A, White M, Antill Y.
Supportive Care in Cancer. 2016; 24 (Suppl1) , PS032
3. Addition of ovarian function suppression to endocrine therapy in premenopausal women with early breast cancer: A meta-analysis.
Chlebowski R, Pan K, Col NF.
SABCS 2016. 2016; P2-09-06
4. 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer.
Thurlimann B, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertsen B, de Azambuja E, Neven P, Lng I, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Price K, Piccart-Gebhart M, Regan MM, Gelber RD, Coates AS, Goldhirsch A.
SABCS 2016. 2016; P2-09-05 (poster)
5. Independent validation of EarlyR gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Buechler S, Gray KP, Gokmen-Polar Y, Willis S, Thurlimann B, Kammler R, Leyland-Jones B, Badve SS, Regan MM.
SABCS 2016 2016; P4-12-01 (poster)
6. Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc .
Ruiz A, Gauthier E, Durairaj C, Huang X, Hoffman J, Finn RS, Moulder S, Joy AA, Ettl J, Rugo HS, Wang D.
SABCS 2016. 2016; P4-22-10 (poster)
7. Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2 advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies.
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Moulder S, Masuda N, Im Y-H, Zhang K, Kim S, Sun W, Schnell P, Huang-Bartlett C, Slamon D.
SABCS 2016. 2016; P4-22-03 (poster)
8. The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Ribi K, Luo W, Burstein HJ, Naughton MJ, Chirgwin J, Ansari RH, Walley BA, Salim M, van der Westhuizen A, Abdi E, Francis PA, Budman DR, Kennecke H, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Regan MM, Bernhard J.
SABCS 2016. 2016; P2-09-09 (poster)
9. Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2 advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies.
Dieras V, Rugo HS, Gelmon K, Finn RS, Cristofanilli M, Loi S, Colleoni M, Lu D, Gauthier E, Huang-Bartlett C, Turner NC, Schnell P.
SABCS 2016. 2016; P4-22-07 (poster)
10. Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC.
Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M, Forbes JF, Buzdar A, Smith R, Howell A.
SABCS 2016. 2016; P2-09-03 (poster)
11. Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1).
Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ.
SABCS 2016. 2016; S5-03.
12. Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial.
Thorat MA, Wagner S, Jones LJ, Levey PM, Bulka K, Hoff R, Sangale Z, Flake II DD, Bundred NJ, Fentiman IS, Forbes JF, Lanchbury JS, Cuzick J.
SABCS 2016. 2016; P1-09-06 (poster)
13. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC.
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M.
SABCS 2016. 2016; S6-05
14. Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study.
Loi S, Asher R, Lee CK, Luen S, Savas P, Kammler R, Dell'Orto P, Blasi OM, Demanse D, JeBailley L, Dolan S, Hackl W, Thuerlimann B, Viale G, Regan M, Colleoni MA.
SABCS 2016. 2016; S1-10
15. Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO.
Di Cosimo S, Appierto V, Tiberio P, Verderio P, Pizzamiglio S, Bottelli S, Iorio M, Baselga J, Piccart M, Huober J, Brase J, de la Pena L, Fumagalli D, de Azambuja E, de Braud F, Daidone MG.
SABCS 2016. 2016; P3-02
16. Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRIO012 study.
Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Patterson I, Aspeslet L, Mackey JR.
SABCS 2016. 2016; P6-16-02 (poster)
17. Maximising recruitment and retention of patients into UK-ANZ POSNOC trial.
Goyal A, Coleman RE, Dodwell D, Fallowfield L, Jenkins VA, Mann B, Reed MW, POSNOC Trial Management Group.
SABCS 2016. 2016; OT3-03-02 (poster)
18. Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer.
Francis PA, Fleming GF, Regan MM, Pagani O, Walley BA, Price KN, Coates AS, Goldhirsch A, Gelber R.
SABCS 2016. 2016; OT3-02-03 (poster)
19. Women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer.
Zdenkowski N, Herrmann A, Hall A, Boyle FM, Butow P.
SABCS 2016. 2016; P3-11-02 (poster)
20. Development of a patient decision aid for women with early-stage breast cancer considering contralateral prophylactic mastectomy.
Agar B.
Asia-Pacific Journal of Clinical Oncology. 2016; 12 (Suppl. S5) , Abstract# 125 (oral presentation)
21. Current Surgical Trials for the Management of Regional Node Disease.
Mann B.
Asia-Pacific Journal of Clinical Oncology. 2016; 12 (Suppl. S5) , Abstract #115 (oral presentation)
22. Decision Aids, Patient Views and Barriers.
Zdenkowski N.
Asia-Pacific Journal of Clinical Oncology. 2016; 12 (Suppl 5) , Abstract #66 (oral presentation)
23. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randooph S, Dieras V, Slamon DJ.
New England Journal of Medicine. 2016; 375 (20) : 1925-1936
24. Development and testing of a decision aid for women contemplating neoadjuvant systemic therapy for operable breast cancer.
Zdenkowski, Nicholas.
Asia-Pacific Journal of Clinical Oncology. 2016; 12 (Suppl. S5) , Abstract #126
25. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA, and the TEXT principal investigators.
Breast Cancer Research 2016; 18:110 : 1-12
26. Evaluating markers for guiding treatment.
Baker SG, Bonetti M.
Journal of the National Cancer Institute. 2016; 108 (9) : djw101; epub 18 May 2016
27. Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII.
Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A, Castiglione M, Colleoni M, Gruber G, for the International Breast Cancer Study Group.
International Journal of Radiation Oncology 2016; 96 (2) : 273-279
28. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00.
Colleoni M, Gray KP, Gelber S, Lang I, Thurlimann B, Gianni L, Abdie EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch.
Journal of Clinical Oncology. 2016; 34 (28) : 3400-3408 (epub 20 June 2016)
29. Treatment adherence and its impact on disease-free survival in the Breast International Group trial of tamoxifen and letrozole, alone and in sequence.
Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Lang I, Colleoni M, Thurlimann B.
Journal of Clinical Oncology. 2016; 34 (21) : 2452-2459 (epub 23 May 2016)
30. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Lang I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.
Breast Cancer Research and Treatment. 2016; 158 (2) : 323-331 (epub 2 July 2016)
31. Still refining adjuvant endocrine therapy in premenopausal women: not too much, not too little.
Wolff AC, Rugo HS.
Journal of Clinical Oncology. 2016; 34 (19) : 2203-2206
32. Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction.
Agar B, Butow P, Jansen J, Phillips K-A, Porter D, CPM DA advisory group.
The Breast. 2016; 28 : 107-120
33. Improved use of clinical variables for prognosis of distant recurrence in patients with ER+ breast cancer treated with 5 years endocrine therapy.
Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM.
Journal of Clinical Oncology. 2016; 34 , (suppl; abstr 566) [transATAC]
34. LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
Saura C, De Azambuja E, Oliveira M, Dubsky PC, Zardavas D, Fesl C, Bardia A, Soberino J, Fornier MN, Boer K, Ng V, Fredrickson JO, Stout T, Singel S, Hsu JY, PIccart-Gebhart MJ, Baselga J, Gnant M.
Journal of Clinical Oncology. 2016; 34 , (suppl; abstr TPS613)
35. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmeopausal women with ER+/HER2- advanced breast cancer (ABC).
Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D, Randooph S, Dieras V, Slamon DJ.
Journal of Clinical Oncology. 2016; 34 , (suppl; abstr 507) oral abstract session.
36. Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial.
Gringas I, Holmes EM, De Azambuja E, Nguyen DHA, Izquierdo MA, Zujewski JA, Inbar MJ, Naume B, Tomasello G, Gnant M, Moreno-Aspitia A, Piccart-Gebhart MJ, Azim HA.
Journal of Clinical Oncology. 2016; 34 , (supp; abstr 604)
37. Are SOFT and TEXT results practice changing and how?
Pagani O, Regan MM, Francis PA.
The Breast. 2016; 27 : 122-125
38. iPrevent(R): a tailored, web-based, decision support tool for breast cancer risk assessment and management.
Collins IM, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P, Weideman P, Steel E, Trainer A, Bressel M, Hopper JL, Cuzick J, Antoniou AC, Phillips K-A.
Breast Cancer Research and Treatment. 2016; 156 (1) : 171-182
39. Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J for the Co-SOFT Investigators.
British Journal of Cancer. 2016; 114 : 956-954
40. Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.
Bergh J, Pritchard KI, Cameron D.
Journal of Clinical Oncology 2016; 34 (9) : 895-897
41. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M, Azim Jr HA, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothe F, Laios I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.
JAMA Oncology. 2016; 2 (2) : 217-224
42. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Lazar AA, Bonetti M, Cole BF, Yi W, Gelber RD.
Clinical Trials. 2016; 13 (2) : 169-179
43. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A.
Journal of Clinical Oncology. 2016; 34 (9) : 927-935
44. Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD, HERA Study Team.
Breast Cancer Research and Treatment. 2016; 155 (1) : 127-132
45. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M, on behalf of the Australia and New Zealand Breast Cancer Trials Group.
Annals of Oncology. 2016; epub 20 March 2016
46. Absolute Benefit of Adjuvant Endocrine Therapies forPremenopausal Women With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD.
Journal of Clinical Oncology. 2016; 34 (19) : 2221-2231
47. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perello A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF.
Journal of Clinical Oncology. 2016; 34 (14) : 1601-1610
48. Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
Dowsett M, Lonning PE, Davidson NE.
Journal of Clinical Oncology. 2016; epub 4 January 2016
49. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, Climent MA, Catalan G, Avella A, Bohn U, Gonzalez-Martin A, Ferrer R, Catalan R, Azaro A, Rajasekaran A, Morales J, Vazquez J, Fleming GF, Price KN, Regan MM.
Journal of Clinical Oncology. 2016; 34 (14) : 1584-1593
50. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, on behalf of the IBIS-II investigators.
The Lancet. 2016; 387 (10021) : 866-873
51. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial.
Piccart-Gebhart M, Holmes E, Baselga J, de Azabuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im Y-H, Huang C-S, Dieras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.
Journal of Clinical Oncology. 2016; 34 (10) : 1034-1042